Stock 4502 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 11:30:00 31/05/2024 am IST 		5-day change 1st Jan Change
4,173 JPY +1.88% Intraday chart for Takeda Pharmaceutical Company Limited +0.94% +2.94%
02/06 GSK blood cancer drug nearly halves risk of death in late-stage trial RE
31/05 Takeda Pharmaceutical Says Recombinant ADAMTS13 Gets Approval Recommendation From European Medicines Agency's CHPM MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 70,29,161 51,53,364 62,29,971 54,23,454 67,62,204 65,47,161 - -
Enterprise Value (EV) 1 1,20,54,743 96,09,054 98,62,522 89,19,170 1,06,11,015 65,64,378 1,05,40,328 1,02,44,147
P/E ratio 40 x 118 x 16.6 x 23.8 x 21.3 x 45.4 x 60.6 x 27.9 x
Yield 3.98% 5.44% 4.52% 5.15% 4.14% 4.49% 4.63% 4.74%
Capitalization / Revenue 3.35 x 1.57 x 1.95 x 1.52 x 1.68 x 1.54 x 1.55 x 1.52 x
EV / Revenue 5.75 x 2.92 x 3.08 x 2.5 x 2.63 x 1.54 x 2.49 x 2.38 x
EV / EBITDA 25.3 x 14 x 9.23 x 8.54 x 9.19 x 6.97 x 9.73 x 8.85 x
EV / FCF -4.81 x 9.99 x 16 x 8.92 x 28.7 x 29.9 x 15.2 x 15.1 x
FCF Yield -20.8% 10% 6.26% 11.2% 3.49% 3.34% 6.57% 6.61%
Price to Book 1.36 x 1.09 x 1.2 x 0.95 x 1.06 x 0.9 x 0.98 x 0.98 x
Nbr of stocks (in thousands) 15,54,780 15,57,849 15,63,355 15,50,444 15,54,530 15,68,934 - -
Reference price 2 4,521 3,308 3,985 3,498 4,350 4,173 4,173 4,173
Announcement Date 14/05/19 13/05/20 11/05/21 11/05/22 11/05/23 09/05/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 20,97,200 32,91,200 31,97,812 35,69,006 40,27,478 42,63,762 42,30,371 42,99,647
EBITDA 1 4,77,415 6,84,057 10,68,940 10,43,995 11,54,905 9,42,077 10,82,951 11,57,434
EBIT 1 2,05,000 1,00,400 5,09,269 4,60,844 4,90,505 2,14,100 2,89,800 4,48,193
Operating Margin 9.77% 3.05% 15.93% 12.91% 12.18% 5.02% 6.85% 10.42%
Earnings before Tax (EBT) 1 94,896 -60,754 3,66,235 3,02,571 3,75,090 52,791 1,34,574 3,21,118
Net income 1 1,09,100 44,200 3,76,005 2,30,059 3,17,017 1,44,067 1,14,130 2,37,358
Net margin 5.2% 1.34% 11.76% 6.45% 7.87% 3.38% 2.7% 5.52%
EPS 2 113.0 28.00 240.7 147.1 204.3 92.09 68.84 149.7
Free Cash Flow 1 -25,07,219 9,61,871 6,17,401 9,99,853 3,70,054 3,44,948 6,92,524 6,76,790
FCF margin -119.55% 29.23% 19.31% 28.01% 9.19% 8.41% 16.37% 15.74%
FCF Conversion (EBITDA) - 140.61% 57.76% 95.77% 32.04% 32.97% 63.95% 58.47%
FCF Conversion (Net income) - 2,176.18% 164.2% 434.61% 116.73% 256.17% 606.79% 285.13%
Dividend per Share 2 180.0 180.0 180.0 180.0 180.0 188.0 193.2 197.6
Announcement Date 14/05/19 13/05/20 11/05/21 11/05/22 11/05/23 09/05/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2020 S2 2021 S1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 S1 2025 Q3 2025 Q4 2026 S1
Net sales 1 16,60,200 16,31,000 15,90,785 8,44,797 17,94,400 9,01,294 8,73,289 9,72,465 10,02,340 19,74,800 10,96,551 9,56,200 10,58,618 10,43,089 21,01,707 11,11,200 10,50,869 10,63,300 10,83,900 20,86,400 11,48,820 10,65,440 20,60,000
EBITDA 1 - - - - - - - - - - - 2,49,972 3,40,072 1,33,355 - 2,91,975 37,144 3,20,925 2,82,725 - 3,68,925 2,02,525 -
EBIT 1 50,300 50,100 2,15,588 97,448 3,46,000 1,16,484 -1,619 1,50,515 1,04,485 2,55,000 1,46,990 88,600 1,68,571 -49,341 1,19,230 1,04,900 -10,055 93,400 75,900 1,47,550 77,867 26,600 2,10,500
Operating Margin 3.03% 3.07% 13.55% 11.54% 19.28% 12.92% -0.19% 15.48% 10.42% 12.91% 13.4% 9.27% 15.92% -4.73% 5.67% 9.44% -0.96% 8.78% 7% 7.07% 6.78% 2.5% 10.22%
Earnings before Tax (EBT) 1 -27,557 -33,197 1,25,561 61,447 2,84,425 72,193 -54,047 1,55,473 64,549 2,20,022 1,07,153 47,900 1,35,033 -95,980 39,053 61,300 -47,500 65,854 46,381 67,650 33,931 -18,719 1,27,500
Net income 1 33,200 11,000 86,548 -16,778 1,83,600 57,769 -11,358 1,05,014 61,786 1,66,800 1,19,127 31,100 89,395 -48,030 41,365 1,05,700 -3,000 52,454 39,231 57,800 30,031 -9,319 97,500
Net margin 2% 0.67% 5.44% -1.99% 10.23% 6.41% -1.3% 10.8% 6.16% 8.45% 10.86% 3.25% 8.44% -4.6% 1.97% 9.51% -0.29% 4.93% 3.62% 2.77% 2.61% -0.87% 4.73%
EPS 2 21.00 - 55.45 -10.27 117.0 37.01 -6.950 67.94 40.06 108.0 76.70 20.03 57.51 -31.00 26.51 67.38 -1.920 30.24 22.27 44.90 23.45 -13.88 62.10
Dividend per Share 2 90.00 - 90.00 - 90.00 - - - - - - - - 94.00 94.00 - 94.00 - 94.00 - - 94.00 -
Announcement Date 31/10/19 13/05/20 29/10/20 28/10/21 28/10/21 03/02/22 11/05/22 28/07/22 27/10/22 27/10/22 02/02/23 11/05/23 27/07/23 26/10/23 26/10/23 01/02/24 09/05/24 - - - - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 50,25,582 44,55,690 36,32,551 34,95,716 38,48,811 37,70,713 39,93,167 36,96,986
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 10.53 x 6.514 x 3.398 x 3.348 x 3.333 x 3.604 x 3.687 x 3.194 x
Free Cash Flow 1 -25,07,219 9,61,871 6,17,401 9,99,853 3,70,054 3,44,948 6,92,524 6,76,790
ROE (net income / shareholders' equity) 3% 0.9% 7.6% 4.2% 5.3% 2.1% 1.8% 3.72%
ROA (Net income/ Total Assets) 1.06% -0.46% 2.85% 2.32% 2.76% 0.36% 1% 1.99%
Assets 1 1,03,34,963 -97,10,018 1,32,09,937 99,18,859 1,14,67,260 3,96,61,656 1,14,17,556 1,19,09,579
Book Value Per Share 2 3,319 3,032 3,309 3,666 4,087 4,636 4,277 4,240
Cash Flow per Share 2 397.0 403.0 599.0 520.0 632.0 557.0 676.0 665.0
Capex 1 1,34,114 2,17,710 2,36,468 1,86,037 6,33,689 4,82,164 6,46,300 4,08,395
Capex / Sales 6.39% 6.61% 7.39% 5.21% 15.73% 11.76% 15.28% 9.5%
Announcement Date 14/05/19 13/05/20 11/05/21 11/05/22 11/05/23 09/05/24 - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Takeda Pharmaceutical Company Limited

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,173 JPY
Average target price
4,801 JPY
Spread / Average Target
+15.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
+2.94% 41.64B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. Financials Takeda Pharmaceutical Company Limited